parainfluenza
virus
piv
envelop
rna
virus
famili
paramyxovirida
piv
common
respiratori
pathogen
known
primarili
caus
infect
children
howev
immun
incomplet
reinfect
occur
piv
infect
immunocompromis
patient
particularli
set
hematolog
malign
solid
organ
transplant
hsct
increasingli
recogn
associ
wide
spectrum
diseas
rang
mild
upper
respiratori
symptom
pneumon
sever
respiratori
failur
mortal
rate
piv
lower
respiratori
diseas
vari
among
studi
reach
report
piv
infect
suspect
diagnosi
made
primarili
detect
piv
antigen
direct
indirect
fluoresc
antibodi
test
nasopharyng
wash
swab
bal
test
limit
sensit
high
specif
viral
cultur
also
use
may
take
sever
day
return
posit
piv
pcr
highli
sensit
specif
may
readili
avail
may
take
time
antibodi
assay
recent
multiplex
pcr
test
becom
avail
multipl
respiratori
pathogen
includ
parainfluenza
virus
univers
chicago
lab
current
perform
pcr
amplif
method
analysi
autom
nest
multiplex
pcr
commerci
avail
assay
test
perform
hous
everyday
turnov
detect
import
respiratori
virus
influenza
influenza
subtyp
influenza
b
respiratori
syncyti
viru
parainfluenza
virus
type
adenoviru
human
metapneumoviru
coronaviru
enterovirusrhinoviru
three
bacteri
pathogen
mycoplasma
pneumonia
chlamydophila
pneumonia
bordetella
pertussi
ct
scan
lung
usual
prefer
imag
modal
identifi
pulmonari
abnorm
radiograph
find
piv
infect
variabl
focal
diffus
interstiti
alveolarinterstiti
infiltr
studi
suggest
multipl
small
noncavit
pulmonari
nodul
might
indic
viral
etiolog
pneumonia
piv
current
antivir
approv
treatment
piv
small
studi
case
report
shown
mix
result
regard
clinic
benefit
aerosol
system
ribavirin
without
iv
gamma
globulin
major
studi
date
fail
demonstr
improv
outcom
treat
patient
term
progress
pneumonia
need
mechan
ventil
durat
ill
mortal
mani
patient
studi
respiratori
copathogen
associ
higher
mortal
organ
identifi
includ
mix
viral
infect
eg
cmv
adenoviru
respiratori
syncyti
viru
superimpos
bacteri
fungal
infect
particularli
aspergillosi
mycobacteri
infect
dual
infect
p
jirovecii
respiratori
viru
also
report
recent
sialidas
fusion
protein
cleav
alpha
gal
linkag
sialic
acid
respiratori
endotheli
cell
surfac
use
hsct
recipi
piv
infect
pneumonia
complet
clinic
respons
patient
partial
control
group
studi
drug
administ
either
oral
inhal
use
dri
powder
inhal
nebul
intub
patient
target
host
protein
piv
bind
rather
viral
structur
pjp
caus
fungu
p
jirovecii
previous
known
p
carinii
howev
p
carinii
understood
separ
speci
infect
rodent
wherea
p
jirovecii
infect
human
henc
name
chang
p
jirovecii
infect
diagnos
person
infect
human
immunodefici
viru
hiv
absolut
lymphocyt
count
nonhivinfect
immunocompromis
patient
increas
risk
invas
fungal
infect
includ
p
jirovecii
consequ
prophylaxi
recommend
tmpsmx
howev
tmpsmx
use
limit
advers
reaction
skin
rash
nausea
vomit
nephrotox
bone
marrow
suppress
dapson
consid
accept
altern
despit
higher
rate
breakthrough
infect
nonhivinfect
patient
pjp
demonstr
acut
clinic
cours
often
delay
treatment
initi
higher
mortal
compar
patient
hiv
infect
tmpsmx
remain
treatment
choic
base
primarili
studi
hivinfect
patient
p
jirovecii
cultur
diagnosi
requir
identif
organ
stain
fluid
induc
sputum
bal
lung
biopsi
specimen
microscopi
dfa
stain
becom
commonli
use
method
studi
among
immunocompromis
patient
without
hiv
lower
organ
burden
poorer
diagnost
yield
convent
stain
specimen
induc
sputum
bal
although
p
jirovecii
realtim
pcr
higher
sensit
specif
dfa
particularli
use
popul
test
may
abl
differenti
colon
true
infect
therefor
tissu
sampl
diagnosi
may
necessari
confirm
pjp
nonhivinfect
patient
key
pointspearlsth
differenti
diagnosi
pulmonari
infiltr
immunocompromis
host
broad
detail
histori
workup
essenti
establish
specif
etiologytissu
sampl
frequent
need
establish
definit
diagnosi
pjp
nonhivinfect
immunocompromis
patientsmultipl
simultan
infecti
noninfecti
patholog
process
common
immunocompromis
patientspjp
consid
differenti
diagnosi
patient
hiv
well
immunocompromis
patient
without
hiv
present
pneumoniath
mainstay
therapi
piv
infect
remain
support
given
lack
evid
support
use
ribavirin
iv
gamma
globulin
although
sialidas
fusion
protein
cleav
alpha
gal
linkag
sialic
acid
respiratori
endotheli
cell
surfac
use
hsct
recipi
piv
infect
good
respons
patientsmultiplex
pcr
test
becom
avail
multipl
respiratori
pathogen
includ
influenza
influenza
subtyp
influenza
b
respiratori
syncyti
viru
parainfluenza
virus
type
adenoviru
human
metapneumoviru
coronaviru
enterovirusrhinoviru
mycoplasma
pneumonia
chlamydophila
pneumonia
bordetella
pertussi
aid
patient
pjp
addit
steroid
recommend
aa
gradient
use
steroid
immunocompromis
patient
pjp
meet
criteria
also
recommendedth
effect
drug
treat
pjp
highdos
trimethoprimsulfamethoxazol
altern
clindamycin
plu
primaquin
test
defici
pentamidin
much
toxic
prognosi
pjp
nonhivinfect
immunocompromis
patient
wors
like
due
delay
diagnosi
acut
present
